公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2016 | 140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations | Park K; Tan E.-H; Zhang L; Hirsh V; O'Byrne K; Boyer M; CHIH-HSIN YANG ; Mok T; Kim M; Paz-Ares L. | Journal of Thoracic Oncology | 2 | 2 | |
2014 | Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis | Popat S; Mok T; CHIH-HSIN YANG ; Wu Y.-L; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L. | Lung Cancer | 46 | 44 | |
2016 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial | Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG ; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. | The Lancet Oncology | 936 | 827 | |
2020 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial | Paz-Ares L.; Kim T.M.; Vicente D.; Felip E.; Lee D.H.; Lee K.H.; CHIA-CHI LIN ; Flor M.J.; Di Nicola M.; Alvarez R.M.; Dussault I.; Helwig C.; Ojalvo L.S.; Gulley J.L.; Cho B.C. | Journal of Thoracic Oncology | 112 | 101 | |
2017 | First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study | Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Paz-Ares L.; Wolf J.; Geater S.L.; Orlov S.; Cortinovis D.; CHONG-JEN YU ; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr | The Lancet | 901 | 771 | |
2019 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH ; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Schütte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Atagi S.; Azuma K.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Koyama R.; Hirashima T.; Kaneda H.; Tomii K.; Fujita Y.; Seike M.; Nishimura N.; Kato T.; Ichiki M.; Saka H.; Hirano K.; Nakahara Y.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Juan-Vidal Ó.; Nadal-Alforja E.; Gil-Bazo I.; Ponce-Aix S.; Rubio-Viqueira B.; Alonso Garcia M.; Felip Font E.; Fuentes Pradera J.; Coves Sarto J.; Lin M.-C.; Su W.-C.; Hsia T.-C.; Chang G.-C.; Wei Y.-F.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. | The Lancet Oncology | 397 | 341 | |
2021 | RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non⇓small cell lung cancer | Nakagawa K.; Nadal E.; Garon E.B.; Nishio M.; Seto T.; Yamamoto N.; Park K.; JIN-YUAN SHIH ; Paz-Ares L.; Frimodt-Moller B.; Zimmermann A.H.; Wijayawardana S.; Visseren-Grul C.; Reck M. | Clinical Cancer Research | 28 | 18 | |